Generic verision of Citus Tab will be reimb-listed next mo.
By Lee, Tak-Sun | translator Hong, Ji Yeon
24.12.27 06:07:35
가나다라
0
With priority marketing authorization valid until August 2015…to challenge a market worth KRW 50 billion
▲SAMA Pharm
The generic version of 'Citus Tab,' SAMA Pharm's treatment for respiratory asthma and allergic rhinitis, will be reimbursement listed in January 2025 for the first time.Four pharmaceutical companies, including Dasan Pharmaceutical, are set to enter the market early through patent avoidance.
According to industry sources on December 26, four products by four pharmaceutical companies, including Dasan Pharmaceutical's 'Prituss Tab. 50mg,' will be listed for reimbursement on January 1.
Among these four products are DongKook Pharmaceutical's 'Pranpid Tab' 50mg, Green Cross' 'Neopran Tab. 50mg,' and Daewoong Bio's 'Cituone Tab. 50mg.'
These products were approved
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)